Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev 2015;23(2):53-68
Date
12/02/2014Pubmed ID
25436468Pubmed Central ID
PMC4323575DOI
10.1097/CRD.0000000000000045Scopus ID
2-s2.0-84922824715 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-normal life expectancies and present with typical age-related cardiovascular conditions. Evidence-based guidelines for medical or surgical management of cardiovascular conditions in individuals with hemophilia are limited. Published recommendations exist for the management of some common cardiovascular conditions (eg, ischemic heart disease, atrial fibrillation), but identifying optimal strategies for anticoagulant or antithrombotic therapy constitutes the primary challenge of managing nonoperative cardiovascular disease (CVD) in PWH. In general, as long as factor concentrates or other hemostatic therapies maintain adequate hemostasis, the recommended medical and surgical management of CVD in PWH parallels that in individuals without hemophilia. The presence of factor inhibitors complicates hemophilia management. Published outcomes of CVD treatment in PWH are similar to those in the general population. Specific knowledge about factor replacement, factor inhibitors, and disease-specific treatment distinguishes the cardiovascular care of PWH from similar care of individuals without this rare bleeding disorder. Furthermore, a multidisciplinary approach incorporating a hematologist with an onsite coagulation laboratory, ideally associated with a hemophilia treatment center, is integral to the management of CVD in PWH.
Author List
Ferraris VA, Boral LI, Cohen AJ, Smyth SS, White GC 2ndAuthor
Gilbert C. White MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Blood CoagulationCardiovascular Agents
Cardiovascular Diseases
Consensus
Disease Management
Hemophilia A
Hemophilia B
Humans
Medication Therapy Management
